VCYT · XBRL financial data

Veracyte financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VCYT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	90	98*	97	114	116	119*	114	130	132	141*	139	150
Gross profit	58	—	62	78	79	—	80	90	91	—	101	109
Research and development	13	19*	16	16	18	19*	18	16	16	21*	27	29
General and administrative	16	24*	26	32	26	27*	34	32	27	17*	24	27
Operating income (loss)	(32)	(36)*	(5)	5	12	4*	3	(5)	23	37*	23	23
Other income (expense)	2	5*	3	3	5	(1)*	5	7	(4)	3*	7	4
Income tax expense (benefit)	(0)	(2)*	(0)	2	2	(2)*	0	2	(0)	(1)*	1	1
Net income (loss)	(30)	(28)*	(2)	6	15	5*	7	(1)	19	41*	29	25
Earnings per share, basic USD per share	(0.41)	(0.39)*	(0.02)	0.07	0.20	0.07*	0.09	(0.01)	0.24	0.52*	0.36	0.32
Earnings per share, diluted USD per share	(0.41)	(0.39)*	(0.02)	0.07	0.19	0.06*	0.09	(0.01)	0.24	0.49*	0.35	0.31
Weighted average shares, basic millions of shares	73	73*	75	77	77	78*	78	78	79	79*	80	80
Weighted average shares, diluted millions of shares	73	73*	75	77	78	82*	80	78	80	84*	81	82

Fiscal quarters (VCYT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	202	216	209	236	274	239	186	219	316	363	263	300
Short-term investments	—	—	—	—	—	—	—	—	—	50	—	—
Accounts receivable	39	40	47	50	49	47	54	51	48	45	50	54
Inventory	16	16	18	19	20	22	24	25	20	21	—	—
Prepaid and other current assets	14	13	16	16	14	15	18	18	15	10	12	13
Total current assets	271	286	290	321	357	372	383	415	449	488	522	575
Right-of-use asset	11	10	11	18	17	48	48	39	37	37	36	35
Goodwill	693	703	754	752	762	746	754	773	767	767	767	767
Total assets	1,125	1,115	1,200	1,234	1,275	1,300	1,315	1,344	1,368	1,406	1,436	1,486
Accounts payable	13	13	12	12	10	9	16	11	6	5	7	8
Accrued liabilities	35	38	30	43	44	44	36	44	48	49	43	48
Total current liabilities	57	61	58	72	70	79	75	76	72	60	56	63
Lease liability, non-current	9	8	8	14	12	43	43	44	36	36	35	34
Total liabilities	71	71	81	102	99	124	120	123	110	96	92	98
Accumulated deficit	(440)	(468)	(470)	(464)	(449)	(444)	(437)	(438)	(419)	(378)	(349)	(323)
Total stockholders' equity	1,054	1,044	1,119	1,133	1,176	1,176	1,195	1,221	1,258	1,310	1,344	1,388
Total liabilities and equity	1,125	1,115	1,200	1,234	1,275	1,300	1,315	1,344	1,368	1,406	1,436	1,486
Common shares outstanding (cover page) millions of shares	73	75	76	77	77	78	78	79	79	79	80	80

Fiscal quarters (VCYT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(30)	(28)*	(2)	6	15	5*	7	(1)	19	41*	29	25
Stock-based compensation	7*	8*	8	10*	9*	10*	11	11*	11*	11*	13	14*
Depreciation and amortization	7*	6*	6	6*	6*	6*	5	5*	5*	5*	5	5*
Net cash from operating activities	14*	16*	(9)	30*	30*	25*	5	34*	45*	53*	35	46*
Purchases of property and equipment	3*	2*	2	3*	2*	4*	2	1*	3*	4*	3	3*
Net cash from investing activities	(3)*	(2)*	3	(3)*	(2)*	(54)*	(52)	(0)*	48*	(5)*	(128)	(14)*
Repayments of long-term debt	0*	0*	—	—	—	year only	—	—	—	—	—	—
Net cash from financing activities	0*	1*	(1)	(0)*	10*	(5)*	(6)	(1)*	3*	(0)*	(7)	4*
Net change in cash	11*	14*	(7)	27*	38*	(35)*	(53)	33*	96*	47*	(99)	36*

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Veracyte	300	150	46*	80.4M	—	Q2 FY26 10-QJun 30, 2026
GRAIL	56	45	(81)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BillionToOne	549	109	9.1*	not reported	—	Q2 FY26 10-QJun 30, 2026
CareDx	250	139	13*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Lumexa Imaging Holdings	70	264	33*	96.1M	—	Q2 FY26 10-QJun 30, 2026
Caris Life Sciences	not reported	264	28*	282.6M	—	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026
Personalis	94	22	(26)*	106.8M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Castle Biosciences	62	104	15*	30.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.